What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Blood pressure
- Cardiology
His scientific interests lie mostly in Internal medicine, Blood pressure, Cardiology, Endocrinology and Surgery.
Left ventricular hypertrophy, Risk factor, Angiotensin II, Losartan and Hemodynamics are subfields of Internal medicine in which his conducts study.
His Angiotensin II study combines topics from a wide range of disciplines, such as Diabetes mellitus, Valsartan and Amlodipine.
His research in Losartan intersects with topics in Framingham Risk Score, Prospective cohort study, Randomized controlled trial and Atenolol.
His research in Blood pressure focuses on subjects like Propranolol, which are connected to Atropine.
Stevo Julius interconnects Stroke, Hazard ratio and Heart rate in the investigation of issues within Cardiology.
His most cited work include:
- Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial (5031 citations)
- Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. (4860 citations)
- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial (2246 citations)
What are the main themes of his work throughout his whole career to date?
Stevo Julius focuses on Internal medicine, Blood pressure, Cardiology, Endocrinology and Left ventricular hypertrophy.
In most of his Internal medicine studies, his work intersects topics such as Surgery.
Blood pressure is a component of his Essential hypertension, Vascular resistance, Prehypertension, Diastole and Angiotensin II studies.
As a member of one scientific family, Stevo Julius mostly works in the field of Cardiology, focusing on Losartan and, on occasion, Randomized controlled trial.
His Left ventricular hypertrophy study integrates concerns from other disciplines, such as Diabetes mellitus, Muscle hypertrophy, Heart disease and Electrocardiography.
His Heart rate research includes themes of Tachycardia and Risk factor.
He most often published in these fields:
- Internal medicine (78.60%)
- Blood pressure (57.21%)
- Cardiology (52.62%)
What were the highlights of his more recent work (between 2004-2021)?
- Internal medicine (78.60%)
- Cardiology (52.62%)
- Blood pressure (57.21%)
In recent papers he was focusing on the following fields of study:
Internal medicine, Cardiology, Blood pressure, Left ventricular hypertrophy and Atrial fibrillation are his primary areas of study.
His study in Heart failure, Myocardial infarction, Stroke, Atenolol and Valsartan falls within the category of Internal medicine.
His work carried out in the field of Cardiology brings together such families of science as Life study, Angiotensin II, Losartan, Hazard ratio and Heart rate.
Stevo Julius focuses mostly in the field of Losartan, narrowing it down to topics relating to Muscle hypertrophy and, in certain cases, Randomized controlled trial.
Stevo Julius has included themes like Diabetes mellitus, Clinical trial and Surgery in his Blood pressure study.
He has researched Left ventricular hypertrophy in several fields, including Electrocardiography, Albuminuria and Vascular disease.
Between 2004 and 2021, his most popular works were:
- Feasibility of Treating Prehypertension with an Angiotensin-Receptor Blocker (761 citations)
- Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study (701 citations)
- Reduction in Albuminuria Translates to Reduction in Cardiovascular Events in Hypertensive Patients. Losartan Intervention for Endpoint Reduction in Hypertension Study (512 citations)
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
